Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

@article{Black2007OnceYearlyZA,
  title={Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis},
  author={Dennis M Black and Pierre Delmas and Richard Eastell and Ian R. Reid and Steven Boonen and Jane A. Cauley and Felicia Cosman and Peter L. Lakatos and Ping Chung Leung and Zulema Man and Carlos A. Mautalen and Peter Mesenbrink and Huilin Hu and John Caminis and Karen Tong and Theresa Rosario-Jansen and Joel S. Krasnow and Trisha F. Hue and Deborah E. Sellmeyer and Erik Fink Eriksen and Steven R Cummings},
  journal={The New England Journal of Medicine},
  year={2007},
  volume={356},
  pages={1809-1822}
}
  • Dennis M Black, Pierre Delmas, +18 authors Steven R Cummings
  • Published 2007
  • Medicine
  • The New England Journal of Medicine
  • Background A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. Methods In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at… CONTINUE READING

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 932 CITATIONS, ESTIMATED 39% COVERAGE

    Zoledronic acid treatment of osteoporosis: effects in men.

    Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.

    FILTER CITATIONS BY YEAR

    2008
    2020

    CITATION STATISTICS

    • 8 Highly Influenced Citations

    • Averaged 45 Citations per year from 2018 through 2020

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 38 REFERENCES

    Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

    Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.